Moderna, Inc. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-06-07

Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-07	Stock Option (Right to Buy)	$219.57	A	42169	Acquired	2031-06-07	Common Stock (42169)	Direct
2021-06-07	Restricted Stock Units	$0	A	18217	Acquired		Common Stock (18217)	Direct
2021-06-07	Restricted Stock Units	$0	A	9108	Acquired		Common Stock (9108)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F3: The shares subject to this restricted stock unit award will vest in full on June 7, 2024, subject to the recipient's continued service.